OKUR

Business Context and Reporting Period

This summary covers the Form 10-Q for Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) for the quarterly period ended June 30, 2024. The company is a smaller reporting company and an emerging growth company. Historically focused on developing mavodelpar for mitochondrial diseases, Reneo suspended development of its only product candidate in December 2023 after its pivotal STRIDE study failed to meet efficacy endpoints. Consequently, the company implemented significant cash preservation measures, including workforce reductions, leaving only eight full-time employees as of the reporting date.

On May 10, 2024, Reneo entered into a definitive merger agreement with OnKure, Inc.. The transaction involves a reverse stock split and a concurrent PIPE investment of up to $85.0 million. The merger is expected to close in the second half of 2024, subject to stockholder approval and other conditions.

Key Financial Metrics

Note: The company has no revenue and no debt obligations other than operating lease liabilities ($0.8 million total).

Material Changes vs. Prior Period

• Significant Reduction in Operating Expenses: Total operating expenses decreased by approximately 70% year-over-year for the six months ended June 30, 2024 ($15.9 million vs. $37.2 million). This was driven by the suspension of mavodelpar development and workforce reductions.
• Research and Development (R&D): R&D expenses plummeted from $25.4 million in the prior year period to $5.5 million in the current period, reflecting the halt in clinical trials and manufacturing activities.
• General and Administrative (G&A): G&A expenses decreased slightly from $11.8 million to $10.4 million. While personnel and facility costs dropped due to layoffs, these savings were partially offset by a $2.7 million increase in legal and advisory fees related to the proposed merger with OnKure.
• Liquidity Position: Total cash and short-term investments decreased from $84.4 million at June 30, 2023, to $76.7 million at June 30, 2024. The company utilized cash for operations and invested in short-term securities, though the overall investment portfolio balance declined due to maturities and lower reinvestment.

Outlook, Risks, and Management Commentary

• Merger with OnKure: The primary strategic focus is the completion of the merger with OnKure, Inc. The transaction includes a concurrent PIPE investment of $65.0 million (expandable to $85.0 million). Upon closing, pre-merger Reneo stockholders are expected to own approximately 22.7% to 24.2% of the new entity (NewCo), depending on the final PIPE amount.
• Liquidity Runway: Management believes the current cash and investment balance of $76.7 million is sufficient to fund operations for at least the next 12 months, assuming the merger does not close and no additional capital is raised.
• Strategic Alternatives: If the merger with OnKure fails to close, the company will reconsider strategic alternatives, which could include a sale of assets, a different merger, or liquidation to distribute cash to stockholders.
• Risks:
  • Merger Failure: There is no assurance the merger will close. Failure could lead to a significant decline in stock price and the need to liquidate.
  • Delisting Risk: The company faces potential delisting from Nasdaq if it fails to meet listing standards, though the proposed reverse stock split is intended to address this.
  • Employee Retention: With only eight employees remaining, the loss of key personnel could jeopardize the ability to consummate the merger or maintain reporting obligations.

Investor Verification Checklist

• Merger Approval Status: Verify the status of stockholder votes required for the OnKure merger and any regulatory conditions.
• PIPE Investment Commitments: Confirm the final amount of the PIPE investment ($65M vs. $85M) as this directly impacts the dilution of existing Reneo shareholders.
• Net Cash Adjustment: Monitor Reneo's net cash balance prior to closing, as the exchange ratio is adjusted if net cash falls below $59.0 million or exceeds $61.0 million.
• Employee Retention: Assess the stability of the remaining eight-person workforce critical to closing the transaction.
• Reverse Stock Split Ratio: Determine the final ratio of the reverse stock split, which will be determined by OnKure subject to Reneo's approval.